-
When the introduction of new drugs by pharmaceutical companies has become the norm, two major drawbacks are gradually emerging
Time of Update: 2022-05-02
4 billion yuan to introduce Dalian Wanchun Brin's first-in-class new drug GEF-H1 activator punabulin, and then with 30 million US dollars, obtained Tianguangshi's third-generation CD20 monoclonal antibody MIL62 in China.
-
New Crown Recombinant Protein Vaccine Phase 3 Clinical Results Announcement Plan to Seek Regulatory Authorization
Time of Update: 2022-05-02
On February 24, Sanofi and GlaxoSmithKline (GSK) announced that the two sides plan to simultaneously submit phase 3 efficacy trial data of their jointly developed recombinant protein new crown vaccine and clinical data as a booster needle to seek regulatory approved .
-
ZSP1273 Tablets, a subsidiary of Zhongsheng Pharmaceutical, received the US FDA Clinical Trial Approval Notice
Time of Update: 2022-05-02
On March 1, Zhongsheng Pharmaceutical issued a corporate announcement. The announcement stated that recently, Zhongsheng Ruichuang, a subsidiary of Zhongsheng Pharmaceutical, has received a drug clin
-
The world's first!
Time of Update: 2022-05-02
CompilenewbornRecently, GlaxoSmithKline (GSK) and Canadian biopharmaceutical company Medicago jointly announced that Health Canada has approved the new crown vaccine product Covifenz (plant-based virus-like particle [VLP], recombinant, adjuvant) .
In December 2021, GSK and Medicago announced the results of the Covifenz global Phase 3 placebo-controlled vaccine efficacy study .
-
3 pharmaceutical companies, R&D expenses announced in 2021
Time of Update: 2022-05-02
Zejing Pharmaceuticals The 2021 performance report disclosed by Zejing Pharmaceuticals shows that the company has a net loss of 414 million yuan in 2021 .
Huiyu Pharmaceutical's 2021 performance report shows that the company will invest 247 million yuan in research and development in 2021, an increase of 178.
-
Moderna mRNA-1345 Initiates Pivotal Phase 3 Clinical Study in Seniors 60 Years and Above
Time of Update: 2022-05-02
Moderna today announced that the RSV Program’s Data and Safety Monitoring Board (DSMB) has approved the initiation of a pivotal Phase 3 clinical study (ConquerRSV) of mRNA-1345 in the elderly population 60 years and older .
-
TOP5 neuroleptic drug Lonno Pharma risperidone oral solution is about to be approved
Time of Update: 2022-05-02
Figure 2: Sales of risperidone oral solution (unit: ten thousand yuan) Source: Terminal competition pattern of public medical institutions in China The sales of risperidone oral solution in China's public medical institutions have steadily increased in recent years.
-
The first China-originated CDK4/6 inhibitor, Hengrui Medicine Dalsili, was launched nationwide
Time of Update: 2022-05-02
On February 26, 2022, the launch meeting of the first Chinese original CDK4/6 inhibitor Dalcil (Ericang®) independently developed by Hengrui Medicine was held in 13 cities across the country, with the
-
2022 Shandong International Elderly Care Service Industry Expo, Smart Elderly Care Industry Exhibition
Time of Update: 2022-05-01
Shandong Lao Expo is committed to creating a booster for the development of the global elderly care industry: "China Shandong International Elderly Care Service Industry Expo & China Shandong International Smart Elderly Care Industry Exhibition" will be held in Jinan International Convention and Exhibition Center BCD from May 20 to 22, 2022 800+ booths are preset, and it is expected that the number of visitors during the three-day exhibition will exceed 50,000 .
-
Over 6 drug reviews since March!
Time of Update: 2022-05-01
On March 3, NMPA information showed that Yangzijiang Pharmaceutical's sodium potassium magnesium sulfate oral solution and levofloxacin sodium chloride injection, which were reported as 3/4 generic drugs, were approved for marketing, which were deemed to have passed the consistency evaluation .
-
Under the normalization of centralized procurement, the enthusiasm of pharmaceutical companies to participate will be further enhanced!
Time of Update: 2022-05-01
According to the notice document on the seventh batch of national procurement-related work issued by Shanghai Sunshine Pharmaceutical Purchasing Network on February 17, about 220 pharmaceutical companies have entered the bureau in this round of centralized procurement, including domestic pharmaceutical companies including Qilu Pharmaceuticals and Kelun Pharmaceuticals.
-
A large number of pharmaceutical companies such as Tofflon and Buchang Pharma issued favorable announcements
Time of Update: 2022-05-01
Buchang Pharmaceutical's Wholly-owned Subsidiary Obtained a Notice of Approval for Drug Clinical Trials On March 1, Buchang Pharmaceutical issued an announcement that Shandong Danhong Pharmaceutical Co.
Zhongsheng Pharmaceutical's holding subsidiary, ZSP1273, a first-class innovative drug, received the US FDA's drug clinical trial approval notice.
-
Another batch of drug reviews!
Time of Update: 2022-05-01
Wanbonde: Review of Phloroglucinol Injection Wanbonde issued an announcement on the evening of March 1, and its subsidiary Wanbonde Pharmaceutical received the "Approval Notice for Supplementary Drug Application" from the State Food and Drug Administration on Phloroglucinol Injection on the same day , the phloroglucinol injection produced by the company passed the consistency evaluation .
-
A large number of drugs will be reduced in price!
Time of Update: 2022-05-01
Subsequently, on February 18, the Liaoning Provincial Public Resource Trading Center issued a notice to voluntarily reduce the price of 27 pharmaceutical products in Liaoning Province, including Huanglian Shangqing Tablets, Yinhuang Granules, Vitamin D Drops and other drugs .
-
Grab the "Spring Light"!
Time of Update: 2022-05-01
Pharmaceutical equipment (Photo source: Pharmaceutical Network) The author learned from the pharmaceutical network platform that since the Spring Festival in 2022, including Bessman, Jinan Ronggan, strength drying, Jinzong Pharmaceutical Machine, Shanghai Hongguan Instrument, Great Wall Technology Industry and Trade, Xuhui Weighing Apparatus A large number of pharmaceutical machine companies such as Xulang Machinery and Xulang Machinery have already started construction, and the workers are fully committed to work and set sail towards new goals .
-
In this popular tumor treatment field, domestic and foreign pharmaceutical companies are accelerating their deployment
Time of Update: 2022-05-01
On March 6, Eli Lilly announced that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) was launched in China for early breast cancer indications.
-
Ride the wind and waves!
Time of Update: 2022-05-01
Antengene: XPOVIO(R) is approved for listing in Singapore In addition to self-developed products, there are also good news that some products introduced by local pharmaceutical companies have been approved in overseas markets recently .
. At present, in addition to Singapore, the product has been approved for new drug marketing applications in China and South Korea .
-
State Food and Drug Administration: Opinions on matters related to the filing of Class I medical devices
Time of Update: 2022-05-01
On March 2, the General Department of the State Food and Drug Administration issued a public solicitation for comments on the "Announcement on Matters Concerning the Filing of Class I Medical Devices (Draft for Comment)" .
-
In the domestic market of anti-anemia drug varieties exceeding 1 billion yuan, a new enterprise has entered the market!
Time of Update: 2022-05-01
Relevant statistics show that, in addition to CSPC, there are four other companies including Chia Tai Tianqing, Jiangsu Wanbang, Jiangxi Shanxiang Pharmaceutical, and Chengdu Beite that have initiated BE trials of roxadustat generic drugs .
-
Yu Xinwei, member of the National Committee of the Chinese People's Political Consultative Conference: Start the national centralized procurement of dental implant consumables as soon as possible
Time of Update: 2022-05-01
disease disease disease health health health hospital hospital hospital Excessive prices inhibit the development of the market, the competitiveness of domestic equipment and consumables manufacturers is weak, and the dental industry chain is difficult to develop on a large scale .
